Vaping is the Best Quit Smoking Method and Needs to be FDA Approved

The FDA Needs to Approve/Clear Vaping

The Food & Drug Administration wants people to suffer. For more than fifty years the FDA has had a hand in the regulation of tobacco products and quit smoking products. Unapproved/Uncleared methods by the FDA restrict primary care physicians and cessation organizations from recommending them, even if they are worlds better. Today, people like to shout out the need for “common sense” policies and regulations for issues like Gun Control, but where are these cries for common sense when it comes to the cessation of tobacco (one of the largest contributors of American deaths)?

Vaping is A Better Choice

The FDA needs to approve vaping because vaping is a better smoking cessation method for people wanting to quit cigarettes. Isn’t it odd that the “approved/cleared” cessation methods also happen to cause unwanted side effects? Conducting a quick search online shows just how disappointing and non-effective nicotine gum has been for potential quitters. “Researchers report in the journal Tobacco Control that nicotine gum and nicotine patches designed to help smokers quit aren’t any more effective than going cold turkey when it comes to keeping smokers off cigarettes for longer than a few months. Beyond that, their ability to curb the need for cigarettes isn’t as clear (Park 2012).”

More Side Effects Please

How about Chantix? Surely that must be better than vaping, right? No, not even close. “When you try to quit smoking, with or without Chantix, you may have symptoms that may be due to nicotine withdrawal (

  • urge to smoke, depressed mood,
  • trouble sleeping, irritability,
  • frustration, anger, feeling anxious,
  • difficulty concentrating, restlessness,
  • decreased heart rate, and increased appetite or weight gain

Some people have had new or worse mental health problems, such as changes in behavior or thinking, aggression, hostility, agitation, depressed mood, or suicidal thoughts or actions while taking or after stopping CHANTIX ( With all those unwanted and possibly fatal side effects, it would be no surprise for smokers to choose to continue smoking.

More Problems Than Vaping

Surely Nicoderm CQ, and the Nicorette patch would be a better choice than vaping? Wrong again. These two methods are more products that come with side effects like, headache, nausea, upset stomach, dizziness, vivid dreams, skin irritation, anxiety, constipation, diarrhea, fatigue, insomnia, irritability, mild itching, burning, redness, upset stomach, and more. So far one thing the above “approved” methods seem to be full of is problems that can at times be considered worse than the smoking problem in the first place.

Lower Risks Than The Others

The FDA needs to approve vaping because it has significantly less adverse effects on lung functions for healthy people as well as asthmatics, and COPD sufferers. According to the American Lung Association, about 85 to 90 percent of all COPD cases are caused by cigarette smoking (2017). So, will vaping be better or worse for people with lung problems? The short answer is maybe but most likely not. A 2017 study shows that a 1-h[our] inhalation session of a high-grade and contaminant-free mixture of propylene glycol and glycerol using a commercially available e-cigarette performed in a controlled environment does not significantly impact pulmonary function or symptoms in both healthy, asthmatic, or COPD subjects (Boulay, Henry, Bossé, Boulet, & Morissette 2017).

No Unwanted Problems

According to Benowitz, and Burbank, studies show nicotine medications and smokeless tobacco have lower risks than cigarette smoke. Since e-cigarettes deliver nicotine without combustion, it poses a lower cardiovascular risk with short-term use (2016). Vaping does not have the unwanted side effects of the “approved” cessation methods discussed here. In fact, the side effects you can expect from vaping are light coughing during the transition period from smoking tobacco to vaping, a favorable fruity or candy-like smell instead of a burnt “death at your door” smell, and a better process for the delivery of nicotine.

A Better Support Platform

The FDA needs to approve vaping because, like any quit smoking organization, vapers have support communities that provide moral and educational support for smokers looking to quit. These vaping communities operate without the benefits (tax write-offs, government funding, etc.) of other cessation groups. Despite being the target of smear campaigns and heavy regulations, vaping communities continue to strive. Why? Because most vaping communities are created and ran by ex-smokers, who made the switch and have a passion for helping other people do the same.

A Call for Change

It is now clear how much worse the approved cessation methods are for people trying to better their lives. A call for common sense policy change is in order. Vaping helps people quit smoking with fewer negative effects, so it is time for the FDA to stop the suffering. The approval of vaping as a cessation method will empower smokers and healthcare professionals to choose a better platform. Finally, once vaping has been approved, vaping communities will have the green light to talk about the benefits of vaping and offer free samples while providing moral and educational support for smokers looking to quit.


==>Learn How to Switch to Vaping<==



American College of Cardiology. Journal Of The American College Of Cardiology, 661378-1391. doi:10.1016/j.jacc.2015.07.037

American Lung Association. Nd. What Causes COPD. Retrieved from

Alice, P. 2012. Nicotine Gum and Patch Don’t Help Smokers Quit Long Term. Retrieved from

Benowitz, N. L., & Burbank, A. D. (2016). Cardiovascular toxicity of nicotine: Implications for electronic cigarette use. Trends In Cardiovascular Medicine, 26515-523. doi:10.1016/j.tcm.2016.03.001

Boulay, M., Henry, C., Bossé, Y., Boulet, L., & Morissette, M. C. (2017). Acute effects of nicotine-free and flavour-free electronic cigarette use on lung functions in healthy and asthmatic individuals. Respiratory Research, 181-5. doi:10.1186/s12931-017-0518-9